Dual Analyst Caution at Human Genome Science (HGSI)
Human Genome Sciences, Inc. (NASDAQ: HGSI) is holding up better than one might expect if analysts still have any power. The good news is that they all got caught the wrong way being bullish before, so maybe this time they…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Human Genome Sciences, Inc. (NASDAQ: HGSI) is holding up better than one might expect if analysts still have any power. The good news is that they all got caught the wrong way being bullish before, so maybe this time they are wrong too. There are two research reports from analysts this morning with downgrades.
RBC Capital Markets cut the rating on Human Genome down to “Sector Perform” this morning, and another downgrade came from Piper Jaffray cutting the rating to Neutral from Overweight.
Shares are down 1.3% at $8.80 after a $8.92 close on Tuesday. The 52-week trading range is $6.51 to $30.15. Keep in mind that shares had been back as high as $10.00 as recently as February 9.
Contact [email protected] for any questions or corrections.
Jon Ogg has been a financial news analyst since 1997. Mr. Ogg set up one of the first audio squawk box services for traders called TTN, which he sold in 2003. He has previously worked as a licensed broker to some of the top U.S. and E.U. financial institutions, managed capital, and has raised private capital at the seed and venture stage. He has lived in Copenhagen, Denmark, as well as New York and Chicago, and he now lives in Houston, Texas. Jon received a Bachelor of Business Administration in finance at University of Houston in 1992. www.247wallst.com.